TENX (Tenax Therapeutics) Moat Score: 2/10 (As of Jul. 02, 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $15.49
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics Moat Score?

Tenax Therapeutics TENX +16.42% 22 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Tenax Therapeutics ranks better than 58.07% on this metric.

Tenax Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Tenax Therapeutics has No Moat: Tenax Therapeutics Inc lacks significant market leadership or proprietary technology. The pharmaceutical industry is competitive, and without strong patents or regulatory barriers, its competitive advantages are transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tenax Therapeutics might have No Moat - Very weak/transient advantages.

Tenax Therapeutics  (NAS:TENX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tenax Therapeutics Moat Score Related Terms

TENX vs RCKT, AVIR, VNDA: Moat Score Comparison

For the Biotechnology subindustry, Tenax Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Moat Score falls into.


TENX
22GF Score
Tenax Therapeutics Inc TENX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Tenax Therapeutics (TENX) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Tenax Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Tenax Therapeutics' Moat Score too high?
Tenax Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Tenax Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Tenax Therapeutics ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Moat Score compare to RCKT and AVIR?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #587 out of 1400 companies for Moat Score. This puts Tenax Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Tenax Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenax Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenax Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.49
Price